[Your Name], Email: your.email@universityx.edu
While ADN-388 holds significant promise, its development is not without challenges. Some of the key hurdles that will need to be addressed include:
| Property | Value | |----------|-------| | Molecular weight | 456.5 Da | | LogP (XlogP3) | 3.1 | | Aqueous solubility (pH 7.4) | 45 µM | | Plasma protein binding (rat) | 92 % | | CYP3A4 IC 50 | > 50 µM | | hERG inhibition (IC 50 ) | 31 µM | adn-388
ADN-388 represents a novel treatment approach for c-MET-driven cancers, with a promising preclinical profile and ongoing clinical trials. The ongoing research and development of ADN-388 have the potential to bring a new treatment option to patients with advanced or recurrent cancers. As scientists continue to explore the mechanisms of ADN-388 and its interactions with other therapies, we may uncover innovative combinations that offer improved efficacy and outcomes for patients.
| Assay | EC 50 (nM) | % Max response | |-------|----------------------|----------------| | PD‑1/PD‑L1 ELISA blocking | 5.3 | 97 | | MLR IFN‑γ restoration | 8.0 | 92 | | Tumor‑T‑cell cytotoxicity (MC38) | 12.5 | 85 | | Cytokine release (IL‑2, TNF‑α) | 10‑15 | No off‑target spikes | [Your Name], Email: your
The mystery of ADN-388 has captivated online communities, with forums and discussion boards dedicated to unraveling its meaning. Theories abound, ranging from the plausible to the fantastical:
Preclinical studies have demonstrated the efficacy and safety of ADN-388 in models of various cancers, including NSCLC, gastric cancer, and pancreatic cancer. In these studies, ADN-388 exhibited potent anti-tumor activity, inhibiting tumor growth and extension in animal models. Additionally, ADN-388 was well-tolerated, with minimal toxicity and side effects observed. As scientists continue to explore the mechanisms of
Given the cryptic nature of the term, several interpretations have emerged:
Oral exposure was linear across the 10‑30 mg kg⁻¹ dose range. No accumulation observed after 7 days of qd dosing.
Notably, the phase I/II trial (NCT03522546) is investigating the combination of ADN-388 with checkpoint inhibitors (e.g., pembrolizumab) for the treatment of patients with NSCLC. Preliminary results from this trial have shown encouraging signs of activity, with some patients achieving durable responses.